Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.

乐伐替尼和帕博利珠单抗联合治疗在帕博利珠单抗预处理的复发性子宫内膜癌中的反应。

• 发表时间: Dec 2022
• 来源期刊: Gynecol Oncol Rep
• DOI: 10.1016/j.gore.2022.101084
• PMID: 36277029
• 文章类型: Case Reports
• 作者列表: Mimura K,Shimomura A,Gota T,Ando K,Kawamura Y,Taniyama T,Oishi H,Shimizu C,Mimura K,Shimomura A,Gota T,Ando K,Kawamura Y,Taniyama T,Oishi H,Shimizu C

关键词: CT, computed tomography; Combination therapy; ICI, immune checkpoint inhibitor; IFN, interferon; Immune checkpoint inhibitor; Immunotherapy; MMR, mismatch repair; MSI, microsatelite instability; PD-1, programmed death-1; Tumor microenvironment; Tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; CT, computed tomography; Combination therapy; ICI, immune checkpoint inhibitor; IFN, interferon; Immune checkpoint inhibitor; Immunotherapy; MMR, mismatch repair; MSI, microsatelite instability; PD-1, programmed death-1; Tumor microenvironment; Tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor

Abstract

Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With relatively few options for late-line therapies for advanced or relapsed endometrial cancer, the use of pretreated therapies may broaden the choice of treatments. Here, we report a case of recurrent microsatellite instability-high endometrial cancer that acquired resistance to pembrolizumab but favorably responded to the lenvatinib and pembrolizumab combination therapy. Lenvatinib combined with pembrolizumab may be effective against endometrial cancer resistant to pembrolizumab monotherapy, encouraging its use regardless of prior administration of immune checkpoint inhibitors. Further investigation on the lenvatinib and pembrolizumab combination therapy and the mechanism underlying its anticancer effect may provide new insights into cancer immunotherapy and tumor microenvironments.

摘要

子宫内膜癌是世界范围内最常见的妇科恶性肿瘤之一。由于晚期或复发性子宫内膜癌的后期治疗选择相对较少，使用预处理疗法可以拓宽治疗选择范围.这里,我们报告了一例复发性微卫星不稳定性-高子宫内膜癌,该病例获得了对帕博利珠单抗的耐药,但对乐伐替尼和帕博利珠单抗联合治疗反应良好.Lenvatinib联合pembrolizumab可能对pembrolizumab单药耐药的子宫内膜癌有效，鼓励其使用，而不管以前的免疫检查点抑制剂的给药。对lenvatinib和pembrolizumab联合治疗及其抗癌作用机制的进一步研究可能为癌症免疫治疗和肿瘤微环境提供新的见解。